Chung-Ang University Researchers Develop Novel DNA Biosensor for Early Diagnosis of Cervical Cancer

Chung-Ang University Researchers Develop Novel DNA Biosensor for Early Diagnosis of Cervical Cancer

Molybdenum disulfide (MoS2) has recently garnered attention among materials science researchers owing to its ability to form two-dimensional nanosheets like graphene. The nanosheets are created by the stacking of S–Mo–S layers interacting via Van der Waals interactions. Additionally, the unique structural, optical, thermal, and electrochemical properties of MoS2 have opened up multiple research avenues across several fields, including the development of biomolecule sensing and chemical detection platforms, optoelectronics, supercapacitors, and batteries.

Traditionally, carbon nanostructures have been employed as an immobilization platform for DNA. In order to substitute carbon with MoS2 as an effective electrochemical DNA sensor, the electrical conductivity of MoS2 needs to be improved considerably. Against this backdrop, Associate Professor Eunah Kang and Mr. Youngjun Kim from the School of Chemical Engineering and Material Science at Chung-Ang University, Korea have recently come up with an elegant solution. The duo has developed an electrochemical DNA biosensor using a graphitic nano-onion/molybdenum disulfide (MoS2) nanosheet composite, which effectively detects human papillomavirus (HPV)-16 and HPV-18, and can serve as an early diagnosis of cervical cancer.

“Nano-onions possess graphitic sp2 structures and are derived from crystalline sp3 nanodiamonds via thermal annealing or laser irradiation,” explains Dr. Kang. Their breakthrough was published in Volume 21 of the Journal of Nanobiotechnology on 10 June 2023.

The researcher duo prepared the novel electrode surface for probing DNA chemisorption by enabling chemical conjugation between two functional groups: acyl bonds on the surfaces of functionalized nano-onions and amine groups present on the modified MoS2 nanosheets. Cyclic voltammetry experiments revealed that a 1:1 composite electrode had an improved rectangular shape compared to that of an MoS2 nanosheet electrode. “This indicated the amorphous nature of the nano-onions with curved carbon layers that facilitated an enhancement in electronic conductivity compared to MoS2 nanosheet alone,” highlights Dr. Kang.

Additionally, the duo measured the sensitivity of their novel electrochemical DNA biosensor device towards HPV-16 and HPV-18 by employing differential pulse voltammetry (DPV) technique in the presence of methylene blue (MB) as a redox indicator. Dr. Kang elaborates: “The DPV current peak was lowered after probe DNA chemisorption and target DNA hybridization. Since the hybridized DNA was double-stranded, it induced less effective MB electrostatic intercalation, resulting in a lower oxidation peak.”

The duo found that, compared to the MoS2 nanosheet electrode, the nano-onion/MoS2 nanosheet composite electrode attained higher current peaks, indicating a greater change in the differential peak. This was attributed to an enhanced conductive electron transfer owing to the nano-onion.

Notably, the target DNAs produced from HPV-16 and HPV-18 Siha and Hela cancer cell lines were detected by the proposed sensor effectively and with high specificity. Consequently, MoS2 nanosheets with improved electrical conductivity facilitated by complexation with nano-onions provides a suitable platform for developing effective and efficient electrochemical biosensors for the early diagnosis of a wide variety of ailments, including cervical cancer.

Furthermore, combining nano-onions or nanodiamonds with different organic biomaterials can facilitate chemical functionality, electron transfer conductivity, light absorption, and more. These, in turn, can lead to innovative disease sensing, targeted drug delivery systems, and biomedical imaging and diagnostics.

Reference

Title of original paper: A graphitic nano-onion/molybdenum disulfide nanosheet composite as a platform for HPV-associated cancer-detecting DNA biosensors

Journal: Journal of Nanobiotechnology

DOI: https://doi.org/10.1186/s12951-023-01948-6

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”